Abstract
The paper provides a brief summary of current preclinical and clinical evidences of dopaminergic system involvement in OCD pathophysiology. We also provide an overview of effectiveness and long-term safety of dopaminergic agents in the treatment of resistant OCD.
Keywords: OCD, resistant-OCD, antipsychotics augmentation, dopamine agents, ondansetron, endogenous, placebo-controlled, quetiapine, olanzapine, aripiprazole, Haloperidol, risperidone augmentation, Sydenham's chorea, amphetamine, cocaine
Current Psychopharmacology
Title: Dopamine Pharmacological Agents in Resistant-OCD
Volume: 1
Author(s): Stefano Pallanti, Giacomo Grassi and Iuliia Burian
Affiliation:
Keywords: OCD, resistant-OCD, antipsychotics augmentation, dopamine agents, ondansetron, endogenous, placebo-controlled, quetiapine, olanzapine, aripiprazole, Haloperidol, risperidone augmentation, Sydenham's chorea, amphetamine, cocaine
Abstract: The paper provides a brief summary of current preclinical and clinical evidences of dopaminergic system involvement in OCD pathophysiology. We also provide an overview of effectiveness and long-term safety of dopaminergic agents in the treatment of resistant OCD.
Export Options
About this article
Cite this article as:
Pallanti Stefano, Grassi Giacomo and Burian Iuliia, Dopamine Pharmacological Agents in Resistant-OCD, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010044
DOI https://dx.doi.org/10.2174/2211556011201010044 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Calcifediol – More than the Stepchild of CKD-MBD Therapy?
Current Vascular Pharmacology Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms
Current Neuropharmacology Astrocytic Adrenoceptors: A Major Drug Target in Neurological and Psychiatric Disorders?
Current Drug Targets - CNS & Neurological Disorders The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Current Drug Targets Improved Oral Bioavailability of Cefuroxime Axetil Utilizing Nanosuspensions Developed by Media Milling Technique
Pharmaceutical Nanotechnology Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings
Current Pharmaceutical Design The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Current Aging Science The Effects of General Anesthetics on Synaptic Transmission
Current Neuropharmacology Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry New Insight into Diabetes Management: From Glycemic Index to Dietary Insulin Index
Current Diabetes Reviews Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets The Association Between the Chronic Use of Non-Steroidal Anti- Inflammatory Drugs and Oxidative and Inflammatory Markers in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Effects of Diphenyl Diselenide on Cholesterol and Glucose Cell Metabolism
Current Medicinal Chemistry Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Current Medicinal Chemistry Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
Current Cancer Drug Targets Rationale for the Development of Cholinesterase Inhibitors as Anti- Alzheimer Agents
Current Pharmaceutical Design Comparable Neuroprotective Effects of Pergolide and Pramipexole on Ferrous Sulfate-Induced Dopaminergic Cell Death in Cell Culture
CNS & Neurological Disorders - Drug Targets An Optimal Approach for Selecting Discriminant Regions for the Diagnosis of Alzheimer's Disease
Current Alzheimer Research